Kura Oncology (NASDAQ:KURA) Shares Gap Down - Here's What Happened

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $17.77, but opened at $16.77. Kura Oncology shares last traded at $17.24, with a volume of 58,885 shares traded.

Analyst Ratings Changes

Several equities research analysts recently weighed in on KURA shares. Stifel Nicolaus lowered shares of Kura Oncology from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. StockNews.com lowered shares of Kura Oncology from a "hold" rating to a "sell" rating in a research note on Thursday, August 22nd. Lifesci Capital upgraded shares of Kura Oncology to a "strong-buy" rating in a research note on Tuesday, October 22nd. Cantor Fitzgerald restated an "overweight" rating on shares of Kura Oncology in a research note on Wednesday. Finally, UBS Group began coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They issued a "buy" rating and a $27.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $28.83.

Kura Oncology Stock Down 0.5 %

The firm's fifty day moving average price is $18.85 and its 200-day moving average price is $19.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94. The firm has a market capitalization of $1.35 billion, a P/E ratio of -8.00 and a beta of 0.86.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.04. Kura Oncology's revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.53) earnings per share. As a group, equities research analysts forecast that Kura Oncology, Inc. will post -2.46 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Kura Oncology by 12.8% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 40,970 shares of the company's stock worth $874,000 after buying an additional 4,659 shares in the last quarter. SG Americas Securities LLC bought a new stake in Kura Oncology during the first quarter worth approximately $110,000. Susquehanna Fundamental Investments LLC bought a new stake in Kura Oncology during the first quarter worth approximately $507,000. ProShare Advisors LLC boosted its holdings in Kura Oncology by 9.7% during the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company's stock worth $384,000 after buying an additional 1,588 shares in the last quarter. Finally, Entropy Technologies LP bought a new stake in Kura Oncology during the first quarter worth approximately $218,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.